Sulfasalazine and Injection site discoloration - a phase IV clinical study of FDA data

Summary:

Injection site discoloration is reported as a side effect among people who take Sulfasalazine (sulfasalazine), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Humira, and have Ankylosing spondylitis.

The phase IV clinical study analyzes which people have Injection site discoloration when taking Sulfasalazine. It is created by eHealthMe based on reports of 95,646 people who have side effects when taking Sulfasalazine from the FDA, and is updated regularly.

What is Sulfasalazine?

Sulfasalazine has active ingredients of sulfasalazine. It is often used in rheumatoid arthritis. eHealthMe is studying from 96,787 Sulfasalazine users. Check the latest studies of Sulfasalazine.

What is Injection site discoloration?

Injection site discoloration is found to be associated with 500 drugs and 598 conditions by eHealthMe. Check the latest studies of Injection site discoloration.

On Jul, 21, 2026

95,646 people reported to have side effects when taking Sulfasalazine.
Among them, 74 people (0.08%) have Injection site discoloration.

Could Sulfasalazine cause Injection site discoloration?

Among these 74 people:

How long have people been on Sulfasalazine when they have Injection site discoloration? *

What is the gender of people who have Injection site discoloration when taking Sulfasalazine? *

female: 70 %
male: 30 %

What is the age of people who have Injection site discoloration when taking Sulfasalazine? *

What are other drugs people take besides Sulfasalazine? *

What are other side effects people have besides Injection site discoloration? *

Injection Site Pain: 26 people, 35.14%
Injection Site Swelling: 18 people, 24.32%
Injection Site Erythema (redness at injection site): 16 people, 21.62%
Joint Pain: 16 people, 21.62%
Pain: 16 people, 21.62%
Headache (pain in head): 16 people, 21.62%
Injection Site Pruritus (severe itching at injection site): 14 people, 18.92%
Weakness: 13 people, 17.57%
Fatigue (feeling of tiredness): 13 people, 17.57%
Injection Site Bruising: 13 people, 17.57%

What are the existing conditions these people have? *

Ankylosing Spondylitis (type of arthritis affecting the spine): 20 people, 27.03%
Pain: 15 people, 20.27%
Gastric Disorder (disease of stomach): 12 people, 16.22%
Cardiac Disorder: 10 people, 13.51%
High Blood Cholesterol: 9 people, 12.16%
Sleep Disorder: 9 people, 12.16%
Insomnia (sleeplessness): 9 people, 12.16%
Stress And Anxiety: 8 people, 10.81%
High Blood Pressure: 8 people, 10.81%
Fibromyalgia (a long-term condition which causes pain all over the body): 8 people, 10.81%

* Approximation only. Some reports may have incomplete information.

Do you take Sulfasalazine and have Injection site discoloration?

- Check whether Injection site discoloration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sulfasalazine:

Sulfasalazine (96,787 reports)

Browse all side effects of Sulfasalazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site discoloration:

Injection site discoloration (500 drugs)

Browse all the conditions that are associated with Injection site discoloration:

Injection site discoloration (598 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sulfasalazine (the active ingredients of Sulfasalazine) and Sulfasalazine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.